What BlossomHill Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 7 | 7 |
| Sells | 0 | 0 |
| Total trades | 21 | 21 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 13,332,995 | 13,332,995 |
| Disposed | 0 | 0 |
| Net activity | +13,332,995 | +13,332,995 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Director | Aug 10 | Open-market buy · P | +312,500 | $16.00 | +$5M | 3,614,034 |
| Chen Bihua | Director | Aug 10 | Derivative Conversion · C | +1,701,541 | — | — | 3,301,534 |
| Chen Bihua | Director | Aug 10 | Derivative Conversion · C | +1,599,993 | — | — | 1,599,993 |
| Schmid John P. | Director | Aug 10 | Open-market buy · P | +6,000 | $16.00 | +$96K | 6,000 |
| Keyes Jason A | Chief Financial Officer | Aug 10 | Open-market buy · P | +700 | $16.00 | +$11.2K | 700 |
| Li Yishan | Executive Chairman | Aug 10 | Derivative Conversion · C | +124,779 | — | — | 124,779 |
| Li Yishan | Executive Chairman | Aug 10 | Derivative Conversion · C | +113,435 | — | — | 1,714,117 |
| Li Yishan | Executive Chairman | Aug 10 | Derivative Conversion · C | +1,600,682 | — | — | 1,600,682 |
| Cui Jingrong Jean | President and CEO | Aug 10 | Derivative Conversion · C | +124,779 | — | — | 124,779 |
| Cui Jingrong Jean | President and CEO | Aug 10 | Derivative Conversion · C | +113,435 | — | — | 1,714,117 |
| Cui Jingrong Jean | President and CEO | Aug 10 | Derivative Conversion · C | +1,600,682 | — | — | 1,600,682 |
| Agrawal Sundeep | Director | Aug 10 | Derivative Conversion · C | +578,524 | — | — | 578,524 |
| Liptak Vincent Paul | General Counsel | Aug 10 | Derivative Conversion · C | +22,687 | — | — | 22,687 |
| Liptak Vincent Paul | General Counsel | Aug 10 | Open-market buy · P | +2,200 | $16.00 | +$35.2K | 111,412 |
| Orbimed Advisors Llc | Director | Aug 10 | Open-market buy · P | +625,000 | $16.00 | +$10M | 2,714,279 |
| Orbimed Advisors Llc | Director | Aug 10 | Derivative Conversion · C | +1,049,283 | — | — | 2,089,279 |
| Orbimed Advisors Llc | Director | Aug 10 | Derivative Conversion · C | +1,039,996 | — | — | 1,039,996 |
| Gordon Carl L | Director | Aug 10 | Open-market buy · P | +625,000 | $16.00 | +$10M | 2,714,279 |
| Gordon Carl L | Director | Aug 10 | Derivative Conversion · C | +1,049,283 | — | — | 2,089,279 |
| Gordon Carl L | Director | Aug 10 | Derivative Conversion · C | +1,039,996 | — | — | 1,039,996 |
Loading...
